AT9283

Bezeichnung:AT9283

CAS-Nr896466-04-9

Englisch Name:AT9283

CBNumberCB02484987

SummenformelC19H23N7O2

Molgewicht381.43

MOL-Datei896466-04-9.mol

AT9283 physikalisch-chemischer Eigenschaften

Dichte	1.45
storage temp.	under inert gas (nitrogen or Argon) at 2–8 °C
Löslichkeit	insoluble in H2O; ≥19.05 mg/mL in DMSO; ≥47.6 mg/mL in EtOH with ultrasonic
Aggregatzustand	solid
pka	10.58±0.10(Predicted)
Farbe	White to off-white

AT9283 Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
AT-9283 is a broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively). It also potently (IC50 = <1 μM) inhibits many other kinases, including serine/threonine kinases as well as receptor and non-receptor tyrosine kinases. As Aurora kinases have roles in mitosis, inhibitors of these kinases, including AT-9283, have potential in cancer therapy. Consistent with this, AT-9283 is effective in preventing proliferation of cancer cells both in vitro and in vivo and this effect may be enhanced by combination therapy with other chemotherapeutics.[Cayman Chemical]
Definition
ChEBI: 1-cyclopropyl-3-[3-[5-(4-morpholinylmethyl)-2-benzimidazolylidene]-1,2-dihydropyrazol-4-yl]urea is a member of benzimidazoles.
Biologische Aktivität
at9283, a synthetic small heterocyclic molecule discovered using a fragment-based approach, is a novel inhibitor of aurora kinase, a family of serine/threonine kinases regulating both mitosis and meiosis, that potently inhibits aurora kinases a and b, with 50% inhibition concentration ic50 value of 3 nm, as well as janus kinases (jaks), abelson kinase (bcrabl t315i) and flt-3. at9283 has been found to be therapeutic in leukemic cells, myeloproliferative disorders and multiple solid tumor cell lines. study results have shown that at9283 exhibits anti-proliferative activity and induces polyploidy and apoptosis in aggressive b-cell nhl cell lines associated with inhibition of aurora kinase b.qi w, liu x, cooke ls, persky do, miller tp, squires m, mahadevan d. at9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive b-cell lymphomas. int j cancer. 2012 jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. epub 2011 nov 19.arkenau ht, plummer r, molife lr, olmos d, yap ta, squires m, lewis s, lock v, yule m, lyons j, calvert h, judson i. a phase i dose escalation study of at9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. ann oncol. 2012 may;23(5):1307-13. doi: 10.1093/annonc/mdr451. epub 2011 oct 19.
target
Aurora A

AT9283 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy